A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma

Trial Profile

A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 May 2016

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Bladder cancer; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Apr 2012 Planned number of patients changed from 80 to 99 as reported by European Clinical Trials Database.
    • 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top